title: GLP-1-based strategies: a physiological analysis of differential mode of action.
abstract: DPP4 inhibitors and GLP-1 receptor agonists used in incretin-based strategies treat Type 2 diabetes with different modes of action. The pharmacological blood GLP-1R agonist concentration targets pancreatic and some extrapancreatic GLP-1R, whereas DPP4i favors the physiological activation of the gut-brain-periphery axis that could allow clinicians to adapt the management of Type 2 diabetes, according to the patient's pathophysiological characteristics.
authors.affiliation: INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, Toulouse, France;
authors.forename: Rémy
authors.initials: R
authors.lastname: Burcelin
authors.forename: Pierre
authors.initials: P
authors.lastname: Gourdy
authors.forename: Stéphane
authors.initials: S
authors.lastname: Dalle
mesh_terms: D000818:Animals; D001921:Brain / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism*; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D054795:Incretins / Q000378:metabolism; D018027:Receptors, Glucagon / Q000378:metabolism
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D054795:Incretins; D018027:Receptors, Glucagon; D052216:Glucagon-Like Peptide 1; D018819:Dipeptidyl Peptidase 4